

ABSTRACT

[Problem] It is desirable to develop a molecule having excellent safety while maintaining anti-tumor activity. It is also desirable to develop an antibody-drug conjugate capable of being systemically administered and delivering a STING agonist specifically to a target cell or organ (for example, a tumor lesion), and a therapeutic agent and/or therapeutic method using the antibody-drug conjugate for diseases related to STING agonist activity, for example, diseases (for example, cancers) to which immunostimulation therapy can be applied. [Solution] An antibody-drug conjugate obtained by conjugating a CDN derivative, which is characterized by the presence of a fused tricyclic substituent, and a specific antibody comprising a mutated Fc region or a functional fragment of the antibody via a linker, and an antibody comprising a mutated Fc region, are provided.

No Fig.